Louis M Messina
Inventions:
Title: Tet1-Dependent Differentiation of Human Hematopoietic Stem Cell towards NKT And γδ T Cells. UMMS15-18; Patent Pending.
-
The invention provides methods of producing hematopoietic stem cells (HSCs) with increased differentiation towards natural killer T cells (NKT) and gamma delta T cells (γδ T cells) for cancer immunotherapy. The HSCs are also functionally superior in their capacity to kill tumor cells, as injection of HSCs overexpressing Tet1 eliminates all of the carcinoma stages of neoplasia.
- Technology: Biologics
- Applications: Cancer, Breast cancer, Colon cancer, Lymphoid malignancies, Myeloma, Ovarian cancer, Prostate cancer, Renal cell carcinoma, Stem cell/Stem cell Therapy, Immunotherapy
Title: METHODS AND COMPOSITIONS TO REDUCE OXIFAATIVE STRESS. UMMS10-19; Patent 9,089,573
-
This patented technology discloses pharmaceutical compositions consisting of L-argnine, tetrahydrobiopterin, and ascorbate to treat diseases of oxidative stress and improve the therapeutic properties of stem cells.
- Technology: Small Molecules
- Applications: Cancer, Stem cell/Stem cell Therapy
- Patent Expiration Dates: 2030-08-23
Innovation Topics: Biologics, Cancer, Breast cancer, Colon cancer, Lymphoid malignancies, Myeloma, Ovarian cancer, Prostate cancer, Renal cell carcinoma, Stem cell/Stem cell Therapy, Immunotherapy, Small Molecules